{"hands_on_practices": [{"introduction": "In clinical practice, Epidermolysis Bullosa Acquisita (EBA) can be challenging to diagnose, often mimicking other blistering diseases, most notably bullous pemphigoid. This exercise simulates a common diagnostic dilemma: a patient with a presumed diagnosis of bullous pemphigoid who is not responding to standard therapy. This practice ([@problem_id:4438218]) will hone your ability to recognize the subtle clinical and laboratory 'red flags' that point towards EBA and to formulate a logical sequence of confirmatory tests.", "problem": "A $56$-year-old man has been labeled as having refractory bullous pemphigoid after $8$ months of generalized tense blisters and erosions despite high-dose systemic corticosteroids at $1$ $\\mathrm{mg/kg/day}$ of prednisone and addition of a steroid-sparing agent. His dermatologist notes several features: blisters preferentially arise at sites of minor trauma on extensor surfaces; numerous healed erosions show scarring with milia; oral mucosal erosions are present; and nail dystrophy has appeared. Laboratory testing to date shows linear deposits of immunoglobulin G (IgG) and complement component 3 (C3) along the basement membrane zone on direct immunofluorescence (DIF). Enzyme-linked immunosorbent assays (ELISA) for type XVII collagen (BP180) and bullous pemphigoid antigen 1 (BP230) have repeatedly been negative. The clinician is reconsidering the diagnosis and aims to determine whether the disease is epidermolysis bullosa acquisita (EBA).\n\nUsing the following fundamental base:\n- The dermal–epidermal junction (DEJ) consists of the basal keratinocyte hemidesmosomal complex and the basement membrane, including the lamina lucida and lamina densa; anchoring fibrils composed of type VII collagen insert into the sublamina densa dermis and secure the epidermis to the dermis.\n- Autoantibodies directed to antigens above the salt-split plane (within or just above the lamina lucida, such as BP180) bind the epidermal “roof” on 1 M sodium chloride salt-split skin, whereas autoantibodies directed to antigens below the split (anchoring fibrils composed of type VII collagen) bind the dermal “floor.”\n- Mechanical stability of the DEJ depends on intact anchoring fibrils; their compromise leads to trauma-induced blistering, scarring, and milia formation.\n- Serration pattern analysis on DIF distinguishes a “u-serrated” pattern (indicative of anchoring fibril involvement) from an “n-serrated” pattern (indicative of hemidesmosomal/lamina lucida antigens).\n\nWhich option best lists criteria to suspect epidermolysis bullosa acquisita in this patient initially labeled as refractory bullous pemphigoid, and names two appropriate confirmatory tests with the expected findings?\n\nA. Suspect EBA when blisters are trauma-induced on extensor surfaces, healing leaves scarring and milia, mucosal involvement is present, disease is refractory to conventional bullous pemphigoid therapy, and BP180/BP230 ELISAs are negative; confirm by indirect immunofluorescence (IIF) on 1 M sodium chloride salt-split skin with linear IgG binding to the dermal floor, and by type VII collagen ELISA demonstrating IgG autoantibodies to type VII collagen.\n\nB. Suspect EBA when an urticarial base, marked pruritus, and eosinophilia predominate with rapid steroid responsiveness; confirm by IIF on salt-split skin showing epidermal roof binding and by BP180 ELISA positivity.\n\nC. Suspect EBA when blistering is widespread without scarring, mucosa is spared, and lesions respond promptly to corticosteroids; confirm by DIF revealing an “n-serrated” pattern and immunoblot detecting bullous pemphigoid antigen 1 at approximately 230 kilodaltons.\n\nD. Suspect EBA when trauma-induced blisters and scarring are present; confirm by IIF on salt-split skin showing epidermal roof binding and by a negative type VII collagen ELISA, which excludes EBA.", "solution": "The problem presented is valid as it is scientifically grounded, well-posed, and objective. It describes a realistic clinical scenario in dermatology requiring differential diagnosis between two autoimmune bullous diseases, bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA), based on established clinical features and diagnostic principles.\n\nThe solution process involves two steps: first, synthesizing the given clinical information and fundamental principles to establish the criteria for suspecting EBA, and second, identifying the appropriate confirmatory diagnostic tests and their expected outcomes for EBA.\n\n**Part 1: Establishing Suspicion for Epidermolysis Bullosa Acquisita (EBA)**\n\nThe patient is a $56$-year-old man initially diagnosed with bullous pemphigoid. However, several features in his presentation are atypical for classic BP and strongly suggestive of an alternative diagnosis, namely EBA.\n\n1.  **Clinical Presentation**: The patient exhibits blisters that arise at sites of minor trauma, particularly on extensor surfaces. This is a mechanobullous phenotype. The provided fundamental base states that \"Mechanical stability of the DEJ depends on intact anchoring fibrils; their compromise leads to trauma-induced blistering\". This directly links the patient's symptom to a pathology of anchoring fibrils. Furthermore, the patient's healed lesions show scarring and milia formation. The base again explicitly states that compromise of anchoring fibrils leads to \"scarring, and milia formation\". These features—trauma-induced blistering, scarring, and milia—are hallmarks of EBA, which targets type VII collagen in the anchoring fibrils. In contrast, classic BP typically heals without scarring. The presence of oral mucosal erosions and nail dystrophy further strengthens the suspicion, as these are common findings in EBA.\n\n2.  **Treatment Response**: The disease has been refractory to high-dose systemic corticosteroids ($1$ $\\mathrm{mg/kg/day}$ of prednisone) plus a steroid-sparing agent. While BP is generally responsive to this regimen, EBA is notoriously difficult to treat and often refractory to conventional therapies. This treatment resistance is a significant clue.\n\n3.  **Laboratory Findings**:\n    -   The initial Direct Immunofluorescence (DIF) showing linear deposits of immunoglobulin G (IgG) and complement component 3 (C3) along the basement membrane zone is consistent with both BP and EBA, and is therefore non-discriminatory on its own.\n    -   Crucially, enzyme-linked immunosorbent assays (ELISA) for the primary BP antigens, type XVII collagen (BP180) and bullous pemphigoid antigen 1 (BP230), have been repeatedly negative. The absence of autoantibodies to these key BP targets makes the diagnosis of BP highly unlikely and mandates consideration of other diseases that present with linear IgG at the basement membrane zone, such as EBA.\n\nIn summary, the combination of a mechanobullous clinical picture with scarring and milia, refractoriness to standard therapy, and negative serology for BP antigens provides a strong basis for suspecting EBA.\n\n**Part 2: Confirmatory Diagnostic Tests for EBA**\n\nTo confirm the diagnosis of EBA, tests must be performed to demonstrate the presence of autoantibodies targeting type VII collagen, the antigen in EBA. The autoantigen, type VII collagen, is located within the anchoring fibrils in the sublamina densa region, which is below the lamina lucida.\n\n1.  **Indirect Immunofluorescence (IIF) on 1 M Sodium Chloride Salt-Split Skin**: The fundamental base explains that 1 M sodium chloride solution induces a cleavage plane within the lamina lucida of the basement membrane. Autoantibodies targeting antigens located superior to this plane (e.g., BP180 in the hemidesmosome) will bind to the epidermal \"roof\" of the split. Autoantibodies targeting antigens inferior to this plane (e.g., type VII collagen in the anchoring fibrils) will bind to the dermal \"floor\". Therefore, to confirm EBA, the patient's serum (containing the autoantibodies) should be tested on salt-split skin, with the expected finding being linear IgG deposition on the **dermal floor**.\n\n2.  **Antigen-Specific Assays**: The definitive diagnosis requires identifying the specific autoantigen. An **ELISA for type VII collagen** is a highly specific test for this purpose. It directly detects circulating IgG autoantibodies against type VII collagen in the patient's serum. A positive result is considered confirmatory for EBA. Other methods such as immunoblotting could also be used to detect antibodies against the $290$ kDa alpha chain of type VII collagen.\n\nAn additional test mentioned in the fundamental base is **serration pattern analysis on DIF**. For EBA, C3 or IgG deposits follow the path of the anchoring fibrils, resulting in a **\"u-serrated\"** pattern. This is in contrast to the **\"n-serrated\"** pattern seen in BP, where deposits follow the contour of the basal keratinocytes. A \"u-serrated\" pattern on the patient's skin biopsy would also be a strong confirmatory finding for EBA.\n\n**Evaluation of Options**\n\n*   **A. Suspect EBA when blisters are trauma-induced on extensor surfaces, healing leaves scarring and milia, mucosal involvement is present, disease is refractory to conventional bullous pemphigoid therapy, and BP180/BP230 ELISAs are negative; confirm by indirect immunofluorescence (IIF) on 1 M sodium chloride salt-split skin with linear IgG binding to the dermal floor, and by type VII collagen ELISA demonstrating IgG autoantibodies to type VII collagen.**\n    This option accurately compiles all the clinical and laboratory clues from the case that point towards EBA. It then correctly identifies two gold-standard confirmatory tests (IIF on salt-split skin and type VII collagen ELISA) and their expected positive findings for EBA (dermal floor binding and positive ELISA result, respectively).\n    **Verdict: Correct.**\n\n*   **B. Suspect EBA when an urticarial base, marked pruritus, and eosinophilia predominate with rapid steroid responsiveness; confirm by IIF on salt-split skin showing epidermal roof binding and by BP180 ELISA positivity.**\n    The criteria for suspicion listed here (urticarial base, pruritus, steroid responsiveness) are characteristic of classic bullous pemphigoid, not EBA. The confirmatory tests and findings (epidermal roof binding, positive BP180 ELISA) are also diagnostic for BP.\n    **Verdict: Incorrect.**\n\n*   **C. Suspect EBA when blistering is widespread without scarring, mucosa is spared, and lesions respond promptly to corticosteroids; confirm by DIF revealing an “n-serrated” pattern and immunoblot detecting bullous pemphigoid antigen 1 (BP230) at approximately 230 kilodaltons.**\n    The suspicion criteria (no scarring, spared mucosa, steroid response) are contrary to the typical presentation of EBA and more aligned with BP. The confirmatory findings (\"n-serrated\" pattern, detection of BP230) are diagnostic for a subset of bullous pemphigoid.\n    **Verdict: Incorrect.**\n\n*   **D. Suspect EBA when trauma-induced blisters and scarring are present; confirm by IIF on salt-split skin showing epidermal roof binding and by a negative type VII collagen ELISA, which excludes EBA.**\n    While the suspicion criteria are partially correct (trauma-induced blisters and scarring are features of EBA), the confirmatory test results are contradictory. Epidermal roof binding on salt-split skin indicates a BP-like antigen location. A negative type VII collagen ELISA, as the option correctly states, argues *against* a diagnosis of EBA, rather than confirming it. The logic is flawed.\n    **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4438218"}, {"introduction": "A definitive diagnosis relies on integrating clinical presentation, histopathology, and serology, but these data streams do not always align perfectly. This practice presents a scenario with apparently discordant findings—strong clinical and serological evidence for EBA but an atypical direct immunofluorescence pattern. By working through this case ([@problem_id:4438299]), you will develop a systematic approach for resolving diagnostic uncertainty and learn the value of advanced techniques in confirming the location of the autoimmune attack.", "problem": "A patient aged $52$ years presents with trauma-induced tense blisters on acral sites that heal with scarring and milia, along with intermittent oral erosions. A perilesional biopsy for direct immunofluorescence (DIF) shows a continuous linear deposition along the basement membrane zone (BMZ) with strong complement component $3$ (C3) and weak immunoglobulin G (IgG). Serum enzyme-linked immunosorbent assay (ELISA) for the noncollagenous domain $1$ (NC1) of type VII collagen is positive at $110$ $\\mathrm{U}/\\mathrm{mL}$ (laboratory cutoff $20$ $\\mathrm{U}/\\mathrm{mL}$). No corticosteroids or immunosuppressants have been administered in the preceding $6$ weeks. You are asked to interpret these discordant findings and to propose a sequence of investigations that reconcile the tissue findings with the serology and establish the correct diagnosis.\n\nFundamental base for reasoning:\n- The dermal–epidermal junction consists of hemidesmosomes (containing bullous pemphigoid antigens), the lamina lucida, lamina densa, and sublamina densa structures (anchoring fibrils composed of type VII collagen).\n- Direct immunofluorescence (DIF) detects in situ deposits; linear BMZ deposition with C3 and IgG is a shared feature across subepidermal autoimmune blistering diseases, with the pattern and target determining the disease entity.\n- The salt-split skin technique induces a split within the lamina lucida using 1 M sodium chloride, exposing antigens on the epidermal (roof) or dermal (floor) side according to their anatomical location.\n- In epidermolysis bullosa acquisita, autoantibodies target type VII collagen (commonly the NC1 domain) localized to anchoring fibrils below the lamina densa; binding on salt-split skin is on the dermal side (floor). In bullous pemphigoid, major antigens are within the hemidesmosome/lamina lucida region and bind the epidermal side (roof).\n- Serration pattern analysis on DIF differentiates antigen localization: an “u-serrated” pattern indicates anchoring fibril targeting (consistent with type VII collagen), whereas an “n-serrated” pattern suggests hemidesmosomal antigens.\n\nWhich option best interprets the discordance and outlines an appropriate plan to reconcile serology with tissue findings?\n\nA. The findings are most consistent with epidermolysis bullosa acquisita. Proceed with indirect immunofluorescence (IIF) on salt-split skin to demonstrate floor-side binding, perform serration pattern analysis to confirm an “u-serrated” pattern, and use immunoblotting or confirmatory ELISA targeting type VII collagen (including NC2 domain if available). Exclude bullous pemphigoid with ELISAs for BP180 (type XVII collagen) and BP230, and repeat DIF on an optimally sampled perilesional biopsy if pre-analytical variables are suspected.\n\nB. The strong C3 with weak IgG indicates bullous pemphigoid; the anti-NC1 ELISA is likely a false positive. Initiate treatment for bullous pemphigoid and, if any further testing is done, expect roof-side binding on salt-split skin IIF; serration pattern analysis adds little value.\n\nC. The complement-predominant linear BMZ deposition with positive anti-NC1 represents mucous membrane pemphigoid with anti-laminin 332. Confirm with laminin 332 ELISA and expect roof-side binding on salt-split skin IIF; disregard serration patterns as they are non-specific.\n\nD. The discordance is best managed by relying solely on the anti-NC1 result and ignoring the DIF, because serology is more specific. Begin high-dose systemic therapy and forego salt-split skin IIF, serration pattern analysis, and immunoblotting, as they rarely change management in this context.", "solution": "### Problem Validation\n\n**Step 1: Extract Givens**\n- **Patient Demographics and Clinical Presentation**: A patient aged $52$ years presents with trauma-induced tense blisters on acral sites that heal with scarring and milia, along with intermittent oral erosions.\n- **Direct Immunofluorescence (DIF)**: A perilesional biopsy shows a continuous linear deposition along the basement membrane zone (BMZ) with strong complement component $3$ (C3) and weak immunoglobulin G (IgG).\n- **Serology**: An enzyme-linked immunosorbent assay (ELISA) for the noncollagenous domain $1$ (NC1) of type VII collagen is positive at $110$ $\\mathrm{U}/\\mathrm{mL}$ (laboratory cutoff $20$ $\\mathrm{U}/\\mathrm{mL}$).\n- **Medication History**: No corticosteroids or immunosuppressants have been administered in the preceding $6$ weeks.\n- **Question**: Interpret the discordant findings and propose a sequence of investigations to reconcile the tissue findings with the serology and establish the correct diagnosis.\n- **Fundamental Base for Reasoning**:\n    - The dermal–epidermal junction (DEJ) anatomy includes hemidesmosomes, lamina lucida, lamina densa, and sublamina densa structures (anchoring fibrils of type VII collagen).\n    - Linear BMZ deposition of C3 and IgG on DIF is common to subepidermal autoimmune blistering diseases.\n    - Salt-split skin technique using 1 M sodium chloride splits the lamina lucida, allowing for localization of immune deposits to the epidermal (roof) or dermal (floor) side.\n    - In epidermolysis bullosa acquisita (EBA), autoantibodies target type VII collagen below the lamina densa, resulting in dermal (floor) side binding on salt-split skin. In bullous pemphigoid (BP), antigens are in the hemidesmosome/lamina lucida, resulting in epidermal (roof) side binding.\n    - Serration pattern analysis on DIF can differentiate antigen localization: an “u-serrated” pattern indicates anchoring fibril targeting (EBA), while an “n-serrated” pattern suggests hemidesmosomal targeting (BP).\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded**: The problem is firmly rooted in the established principles of dermatology, immunology, and pathology. The clinical description, laboratory findings, and diagnostic techniques (DIF, ELISA, salt-split skin, serration analysis) are standard in the workup of autoimmune blistering diseases. The scenario of \"discordant\" findings is a realistic clinical challenge.\n- **Well-Posed**: The problem is well-posed, presenting a clear set of data and a specific question that can be answered through logical deduction based on the provided fundamental principles. A coherent diagnostic pathway can be formulated.\n- **Objective**: The problem statement is presented in objective, clinical language, free from subjective claims or bias.\n\n**Step 3: Verdict and Action**\nThe problem is scientifically sound, well-posed, objective, and contains sufficient information to formulate a logical solution. The apparent contradiction in the data is the central puzzle to be solved, not a flaw in the problem statement. The problem is **valid**.\n\n### Solution Derivation\n\nThe core of this problem is to reconcile a set of clinical and laboratory findings that appear partially contradictory.\n\n1.  **Analysis of Clinical Findings**: The patient's presentation with trauma-induced blisters on acral sites, healing with scarring and milia, is the classic mechanobullous phenotype highly characteristic of epidermolysis bullosa acquisita (EBA). The presence of oral erosions is also common in EBA.\n\n2.  **Analysis of Serological Findings**: The serum ELISA is strongly positive for antibodies against the NC1 domain of type VII collagen ($110$ $\\mathrm{U}/\\mathrm{mL}$, where the cutoff is $20$ $\\mathrm{U}/\\mathrm{mL}$). Type VII collagen is the autoantigen in EBA. A positive ELISA of this magnitude is a highly specific and strong piece of evidence for EBA.\n\n3.  **Analysis of Direct Immunofluorescence (DIF)**: The DIF shows a continuous linear deposition at the BMZ, which is the hallmark of the pemphigoid group of diseases (including EBA and BP). However, the pattern of deposition is described as \"strong C3 and weak IgG\". While the classic DIF pattern for EBA is strong linear IgG (often of the IgG4 subclass) with or without C3, a C3-predominant or even IgG-negative pattern is a known, albeit less common, variant. This pattern is more classically associated with bullous pemphigoid (BP), where IgG1 antibodies are potent activators of the classical complement pathway, leading to strong C3 deposition that can sometimes overshadow the IgG deposits.\n\n4.  **Reconciliation of Findings**: We have strong clinical evidence (scarring, milia, trauma-induced blisters) and strong, specific serological evidence (anti-type VII collagen ELISA) for EBA. The only \"discordant\" finding is the C3-predominant DIF pattern. Given that this pattern is a recognized variant in EBA, the most logical initial conclusion is that the patient has EBA with an atypical immunofluorescence profile. The diagnostic task is to confirm this hypothesis and definitively rule out the primary differential diagnosis, BP.\n\n5.  **Formulating a Diagnostic Plan**: To resolve the ambiguity, further tests are required to precisely locate the immune deposits within the BMZ, thereby distinguishing EBA (sub-lamina densa) from BP (lamina lucida/hemidesmosome).\n    - **Step 1: Antigen Localization**: The most critical next step is to use the salt-split skin technique. This can be done via indirect immunofluorescence (IIF) using the patient's serum on prepared normal skin, or via direct immunofluorescence on a salt-split section of the patient's own biopsy. Given the positive serology, IIF on salt-split skin is an excellent choice. A diagnosis of EBA would be confirmed by binding of the patient's antibodies to the dermal side (floor) of the split. BP would show binding to the epidermal side (roof).\n    - **Step 2: Morphological Confirmation**: Serration pattern analysis on the original DIF slide (or a new one) provides an elegant way to confirm the antigen location without splitting the tissue. An \"u-serrated\" pattern would strongly support the sub-lamina densa localization of EBA, while an \"n-serrated\" pattern would favor BP. This test directly addresses the DIF findings.\n    - **Step 3: Confirmatory Serology and Exclusion of Differentials**: To be thorough, it is wise to confirm the antibody specificity via another method, such as immunoblotting, which should show reactivity against the type VII collagen protein ($290$ kDa or its $145$ kDa NC1 domain). Concurrently, to formally exclude BP, ELISAs for the BP antigens, BP180 (type XVII collagen) and BP230, should be performed. Negative results for these would virtually rule out BP.\n    - **Step 4: Re-evaluation**: If results remain contradictory after this extensive workup, one might consider pre-analytical errors in the initial biopsy (e.g., sampling from an inflamed site where IgG was consumed, leaving only complement) and consider a repeat biopsy from an optimal, non-inflamed perilesional site.\n\n### Option-by-Option Analysis\n\n**A. The findings are most consistent with epidermolysis bullosa acquisita. Proceed with indirect immunofluorescence (IIF) on salt-split skin to demonstrate floor-side binding, perform serration pattern analysis to confirm an “u-serrated” pattern, and use immunoblotting or confirmatory ELISA targeting type VII collagen (including NC2 domain if available). Exclude bullous pemphigoid with ELISAs for BP180 (type XVII collagen) and BP230, and repeat DIF on an optimally sampled perilesional biopsy if pre-analytical variables are suspected.**\n- This option correctly identifies EBA as the leading diagnosis based on the weight of clinical and serological evidence. It proposes a comprehensive, logical, and state-of-the-art diagnostic plan that directly addresses the ambiguity. It includes the key differentiating tests (salt-split skin IIF, serration analysis), confirmatory tests (immunoblotting), and exclusionary tests (BP antigen ELISAs). The final consideration of pre-analytical variables is also appropriate.\n- **Verdict: Correct.**\n\n**B. The strong C3 with weak IgG indicates bullous pemphigoid; the anti-NC1 ELISA is likely a false positive. Initiate treatment for bullous pemphigoid and, if any further testing is done, expect roof-side binding on salt-split skin IIF; serration pattern analysis adds little value.**\n- This option makes two critical errors. First, it prematurely dismisses a highly specific and strongly positive ELISA result as a \"false positive\" while prioritizing a non-specific DIF pattern. Second, it incorrectly states that serration pattern analysis \"adds little value,\" when in fact it is a powerful tool for differentiating EBA and BP. Initiating treatment based on this flawed interpretation would be inappropriate.\n- **Verdict: Incorrect.**\n\n**C. The complement-predominant linear BMZ deposition with positive anti-NC1 represents mucous membrane pemphigoid with anti-laminin 332. Confirm with laminin 332 ELISA and expect roof-side binding on salt-split skin IIF; disregard serration patterns as they are non-specific.**\n- This option incorrectly conflates different diseases. The positive anti-type VII collagen (NC1) ELISA specifically points to EBA, not anti-laminin 332 mucous membrane pemphigoid (MMP). While MMP is in the differential diagnosis for oral erosions, the serology does not support it as the primary diagnosis. Furthermore, anti-laminin 332 antibodies cause floor-side binding on salt-split skin (not roof-side), but target a different antigen. The claim that serration patterns are non-specific is false.\n- **Verdict: Incorrect.**\n\n**D. The discordance is best managed by relying solely on the anti-NC1 result and ignoring the DIF, because serology is more specific. Begin high-dose systemic therapy and forego salt-split skin IIF, serration pattern analysis, and immunoblotting, as they rarely change management in this context.**\n- This option promotes a reckless oversimplification. While serology is very specific, ignoring discordant data from other tests is poor scientific and clinical practice. Foregoing confirmatory tests is not justified; these tests are crucial for establishing a definitive diagnosis, which is essential given that EBA can be very difficult to treat and has a different prognosis from BP. The statement that these tests \"rarely change management\" is factually incorrect; they are the standard of care for resolving such diagnostic dilemmas.\n- **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4438299"}, {"introduction": "Beyond simply ordering a test and noting if it is positive or negative, a sophisticated clinician understands how to quantify the impact of that result on diagnostic certainty. This exercise moves from qualitative interpretation to quantitative analysis using Bayes' theorem. You will calculate the post-test probability of EBA ([@problem_id:4438278]), providing a concrete measure of how a positive ELISA result revises the likelihood of disease and reinforcing the importance of considering pre-test probability in clinical reasoning.", "problem": "A clinician suspects epidermolysis bullosa acquisita (EBA) based on a mechanobullous phenotype and orders a type VII collagen non-collagenous domain 1 (NC1) Enzyme-Linked Immunosorbent Assay (ELISA). At a positivity cutoff of $20$ U/mL, the test has sensitivity $0.85$ and specificity $0.95$. The clinician’s pretest probability for EBA, grounded in clinical and histopathologic assessment, is $0.20$. Using Bayes’ theorem and the standard definitions of sensitivity, specificity, and probability, compute the post-test probability of EBA given a positive NC1 ELISA result at the stated cutoff. Express your final answer as a decimal rounded to four significant figures.", "solution": "To compute the post-test probability of disease given a positive test, start from Bayes’ theorem and the foundational definitions of sensitivity, specificity, and probability.\n\nLet $D$ denote the event that the patient truly has epidermolysis bullosa acquisita (EBA), and let $T^{+}$ denote a positive test result on the type VII collagen non-collagenous domain 1 (NC1) Enzyme-Linked Immunosorbent Assay (ELISA) at the specified cutoff.\n\nBy Bayes’ theorem, the posterior probability of disease given a positive result is\n$$\n\\mathbb{P}(D \\mid T^{+}) \\;=\\; \\frac{\\mathbb{P}(T^{+} \\mid D)\\,\\mathbb{P}(D)}{\\mathbb{P}(T^{+} \\mid D)\\,\\mathbb{P}(D) + \\mathbb{P}(T^{+} \\mid \\neg D)\\,\\mathbb{P}(\\neg D)}.\n$$\nFrom the definitions:\n- Sensitivity is $\\mathbb{P}(T^{+} \\mid D)$.\n- Specificity is $\\mathbb{P}(T^{-} \\mid \\neg D)$, so the false-positive rate is $\\mathbb{P}(T^{+} \\mid \\neg D) = 1 - \\text{specificity}$.\n- The pretest probability is $\\mathbb{P}(D)$, hence $\\mathbb{P}(\\neg D) = 1 - \\mathbb{P}(D)$.\n\nAlternatively, using likelihood ratios derived from the same definitions, the positive likelihood ratio is\n$$\n\\text{LR}^{+} \\;=\\; \\frac{\\text{sensitivity}}{1 - \\text{specificity}} \\;=\\; \\frac{\\mathbb{P}(T^{+} \\mid D)}{\\mathbb{P}(T^{+} \\mid \\neg D)}.\n$$\nBayes’ theorem in odds form states that the posterior odds equal the prior odds multiplied by the likelihood ratio:\n$$\n\\text{Posterior odds} \\;=\\; \\text{Prior odds} \\times \\text{LR}^{+},\n$$\nwhere\n$$\n\\text{Prior odds} \\;=\\; \\frac{\\mathbb{P}(D)}{1 - \\mathbb{P}(D)}.\n$$\nFinally, convert posterior odds back to probability via\n$$\n\\mathbb{P}(D \\mid T^{+}) \\;=\\; \\frac{\\text{Posterior odds}}{1 + \\text{Posterior odds}}.\n$$\n\nNow substitute the given values:\n- Sensitivity $= 0.85$ so $\\mathbb{P}(T^{+} \\mid D) = 0.85$.\n- Specificity $= 0.95$ so $\\mathbb{P}(T^{+} \\mid \\neg D) = 1 - 0.95 = 0.05$.\n- Pretest probability $\\mathbb{P}(D) = 0.20$, hence $\\mathbb{P}(\\neg D) = 1 - 0.20 = 0.80$.\n\nCompute the positive likelihood ratio:\n$$\n\\text{LR}^{+} \\;=\\; \\frac{0.85}{0.05} \\;=\\; 17.\n$$\nCompute the prior odds:\n$$\n\\text{Prior odds} \\;=\\; \\frac{0.20}{0.80} \\;=\\; 0.25.\n$$\nCompute the posterior odds:\n$$\n\\text{Posterior odds} \\;=\\; 0.25 \\times 17 \\;=\\; 4.25.\n$$\nConvert to posterior probability:\n$$\n\\mathbb{P}(D \\mid T^{+}) \\;=\\; \\frac{4.25}{1 + 4.25} \\;=\\; \\frac{4.25}{5.25} \\;=\\; \\frac{17}{21} \\;\\approx\\; 0.809523\\ldots\n$$\n\nRounded to four significant figures as required, the post-test probability is $0.8095$.", "answer": "$$\\boxed{0.8095}$$", "id": "4438278"}]}